vidarabine
Also known as CI-673, Vira-A®, 2-(6-AMINO-purin-9-yl)-5-hydroxymethyl-tetrahydro-furan-3,4-diol, 9-beta-D-Arabinofuranosyl-9H-purin-6-amine, 9-beta-D-arabinofuranosyl-adenine, 9-beta-D-Arabinofuranosyladenine, 9-β-D-arabinofuranosyl-9H-purin-6-amine, 9-β-D-arabinofuranosyladenine
Vidarabine or 9-β-D-arabinofuranosyladenine (ara-A) is an antiviral drug which is active against herpes simplex and varicella zoster viruses.
Research
5,777 papers- Vidarabine is neither a potent nor a selective AC5 inhibitor.Biochemical pharmacology · 2014
- Vidarabine: a preliminary review of its pharmacological properties and therapeutic use.Drugs · 1980
- Vidarabine encephalopathy.Journal of neurology, neurosurgery, and psychiatry · 1984
- An Enzymatic Flow-Based Preparative Route to Vidarabine.Molecules (Basel, Switzerland) · 2020
- Vidarabine (Vira-A).The Medical letter on drugs and therapeutics · 1977
via PubMed
~8 min read
Article
11 sectionsContents
- Medical use
- Selectivity
- Clinical indication
- Pharmacokinetics
- Mode of action
- Mode of resistance
- Discovery
- Synthesis
- Chemical synthesis
- Biosynthesis
- References
Vidarabine or 9-β-D-arabinofuranosyladenine (ara-A) is an antiviral drug which is active against herpes simplex and varicella zoster viruses.
== Medical use == === Selectivity ===
Gallery (2)
Connections
Categories
Anti-herpes virus drugsArabinosidesChemical articles with multiple CAS registry numbersChemicals using indexlabelsDrugboxes which contain changes to verified fieldsDrugboxes which contain changes to watched fieldsDrugs with no legal statusECHA InfoCard ID from WikidataHydroxymethyl compoundsMultiple chemicals in Infobox drugPurinesSRI International